Xoma Opts For Lower Raptiva Royalty In Lieu Of Loan Repayment To Genentech

Under the revised agreement, Xoma will receive a “mid-single digit royalty” on worldwide sales of Raptiva plus a royalty based on U.S. sales above a certain level. In return, Genentech will eliminate Xoma’s $40 mil. balance on a development loan.